Clinical Trial Update: A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2 and Phase 3 clinical trial evaluating SHR-1701 in combination with BP102 and XELOX as first-line treatment for metastatic colorectal cancer was termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• BP102
• SHR-1701
• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Metastatic Colorectal Cancer (mCRC) | Phase 2, Phase 3 | Status: TERMINATED